2CVU Stock Overview
Engages in the development, manufacturing, and sale of medical products, services and technologies in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ConvaTec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£12.30 |
| 52 Week High | UK£13.30 |
| 52 Week Low | UK£10.10 |
| Beta | 0.70 |
| 1 Month Change | 9.82% |
| 3 Month Change | 8.85% |
| 1 Year Change | -0.81% |
| 3 Year Change | 41.38% |
| 5 Year Change | 85.13% |
| Change since IPO | 36.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2CVU | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -3.1% | 0.2% | -0.5% |
| 1Y | -0.8% | -11.2% | 15.5% |
Return vs Industry: 2CVU exceeded the German Medical Equipment industry which returned -14.4% over the past year.
Return vs Market: 2CVU underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 2CVU volatility | |
|---|---|
| 2CVU Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2CVU has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2CVU's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,489 | Karim Bitar | www.convatecgroup.com |
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies in Europe, North America, and internationally. The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma.
ConvaTec Group PLC Fundamentals Summary
| 2CVU fundamental statistics | |
|---|---|
| Market cap | €6.18b |
| Earnings (TTM) | €175.05m |
| Revenue (TTM) | €2.10b |
35.3x
P/E Ratio2.9x
P/S RatioIs 2CVU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2CVU income statement (TTM) | |
|---|---|
| Revenue | US$2.29b |
| Cost of Revenue | US$1.00b |
| Gross Profit | US$1.29b |
| Other Expenses | US$1.10b |
| Earnings | US$190.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Jul 29, 2025
| Earnings per share (EPS) | 0.093 |
| Gross Margin | 56.29% |
| Net Profit Margin | 8.32% |
| Debt/Equity Ratio | 66.5% |
How did 2CVU perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield69%
Payout RatioDoes 2CVU pay a reliable dividends?
See 2CVU dividend history and benchmarks| ConvaTec Group dividend dates | |
|---|---|
| Ex Dividend Date | Apr 22 2025 |
| Dividend Pay Date | Jun 12 2025 |
| Days until Ex dividend | 37 days |
| Days until Dividend pay date | 88 days |
Does 2CVU pay a reliable dividends?
See 2CVU dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 19:46 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ConvaTec Group PLC is covered by 32 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hassan Al-Wakeel | Barclays |
| Samuel England | Berenberg |
| Marianne Bulot | BofA Global Research |